EUCTR2006-002621-23-ES进行中（未招募）1 期
Estudio abierto, multicéntrico, de 54 semanas de duración que evalúa la seguridad y tolerabilidad a largo plazo de la combinación de aliskiren 300 mg y valsartan 320 mg en pacientes con hipertensión esencial
ovartis Farmaceutica S.A.0 个研究点目标入组 0 人开始时间: 2007年1月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •- Outpatients 18 years of age and older.
- •- Male or female patients are eligible.
- •- For newly diagnosed/untreated patients with essential hypertension defined as
- •DBP > 90 and <110 mmHg at Visit 1 and Visit 2.
- •- For previously treated patients with essential hypertension defined as DBP > 90
- •and < 110 mmHg after 2 to 4 weeks of washout (Visits 3 or 4).
- •- Patients who are eligible and able to participate in the study, and who consent to
- •do so after the purpose and nature of the investigation has been clearly explained
- •to them (written informed consent).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Previously treated in an aliskiren study that contained the treatment group of the
- •combination of aliskiren and valsartan and had been randomized or enrolled into
- •the active drug treatment period of that study.
- •- Severe hypertension (msDBP >110 mmHg and/or msSBP > 180 mmHg)
- •- Pregnant or nursing (lactating) women
- •- Women of child-bearing potential (WOCBP)
- •- History or evidence of a secondary form of hypertension
- •- Any history of hypertensive encephalopathy or cerebrovascular accident, or history
- •within 12 months from visit 1 for transient ischemic attack (TIA), myocardial
- •infarction, coronary bypass surgery, or any percutaneous coronary intervention
- •- Previous or current diagnosis of heart failure (NYHA Class III –IV)
- •- Serum potassium > 5.3 mEq/L (mmol/L) at Visit 1.
- •- Patients with Type 1 or Type 2 diabetes mellitus who are not well controlled based
- •on the investigator's clinical judgment. Patients with diabetes mellitus enrolled in
- •this study should be well controlled. It is recommended that patients currently
- •being treated for diabetes mellitus be on a stable dose of antidiabetic medication
- •for at least 4 weeks prior Visit 1.
- •- Current angina pectoris requiring pharmacological therapy except for nitrates.
- •- Second or third degree heart block without a pacemaker.
- •- Atrial fibrillation or atrial flutter at Visit 1, or potentially life-threatening arrhythmia
- •during the 12 months prior to Visit 1.
- •- Any medication, surgical or medical condition which might significantly alter the
- •absorption, distribution, metabolism, or excretion of medications including, but not
- •limited to any of the following:
- •History of major gastrointestinal tract surgery such as gastrectomy,
- •gastroenterostomy, or bowel resection.
- •History of active inflammatory bowel disease during the 12 months prior to Visit 1.
- •Currently active gastritis, duodenal or gastric ulcers, or history of gastrointestinal
- •bleeding during the 3 months prior to Visit 1.
- •Evidence of hepatic disease as determined by any one of the following: ALT or AST
- •values exceeding 3x ULN at Visit 1, a history of hepatic encephalopathy, a history
- •of esophageal varices, or a history of portocaval shunt.
- •Evidence of renal impairment as determined by any one of the following: serum
- •creatinine > 1.5x ULN at Visit 1, a history of dialysis, or a history of nephrotic
- •Current treatment with cholestyramine or colestipol resins.
- •- History of hypersensitivity to any of the medications or drugs belonging to the
- •similar therapeutic class (ARB's, ACE-I, thiazide diuretics, or other sulfonamide
- •derived drugs) as the study drugs.
- •- History of malignancy of any organ system, treated or untreated, within the past 5
- •years whether or not there is evidence of local recurrence or metastases, with the
- •exception of localized basal cell carcinoma of the skin.
- •- History or evidence of drug or alcohol abuse within the last 12 months.
- •- Any surgical or medical condition which in the opinion of the investigator may place
- •the patient at higher risk from his/her participation in the study, or is likely to
- •prevent the patient from complying with the requirements of the study or
- •completing the study.
- •- Use of other investigational drugs at the time of enrollment, or within 30 days or 5
- •halflives of enrollment, whichever is longer.
- •- If subject is expected to continue or start any medication listed in secti
研究者
相似试验
进行中（未招募）
不适用
Estudio multicéntrico, abierto, de 28 a 54 semanas de duración, para evaluar la seguridad y la tolerabilidad a largo plazo de la combinación de aliskiren/amlodipino/hidroclorotiazida, en pacientes con hipertensión esencialHipertensiónMedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionEUCTR2008-001242-10-ESovartis Farmacéutica S.A.500
进行中（未招募）
1 期
Etude ouverte, multicentrique, de 24 semaines, évaluant l'efficience clinique de la forme Exelon patch 10 cm2 chez des patients avec une maladie d'Alzheimer (MMSE 10-26) - EXTRAMaladie d'AlzheimerMedDRA version: 9.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseEUCTR2007-003405-27-FROVARTIS PHARMA SAS
进行中（未招募）
不适用
Estudio multicéntrico, abierto, de seguimiento para evaluar la seguridad y eficacia a largo plazo de lacosamide en sujetos con neuropatía diabética distal dolorosa, que incluye un subestudio de retirada aleatorizado, doble ciego de tiempo limitado. (A multicenter, open-label, follow-on trial to assess the long-term safety and efficacy of lacosamide in subjects with painful distal diabetic neuropathy including a double-blind, randomized time point withdrawal subtrial)europatía diabética distal dolorosa(Painful distal diabetic neuropathy)MedDRA version: 9.0Level: LLTClassification code 10012680EUCTR2004-000551-42-ESSCHWARZ BIOSCIENCES GmbH530
进行中（未招募）
不适用
Estudio de 24 semanas de duración, multicéntrico, abierto y comparativo de dos estrategias (insulina glargina frente a insulina premezclada) para el tratamiento de pacientes con diabetes de tipo 2 que han fracasado a los fármacos oralesA 24-week, open, multicenter, comparative study of 2 strategies (including insulin glargine versus premixed insulin) for the therapeutic management of patients with type 2 diabetes failing oral agents - GALAPAGOSDiabetes tipo 2 con fracaso a las intervenciones en el estilo de vida y a los fármacos oralesMedDRA version: 11Level: LLTClassification code 10063624Term: Diabetes melitus tipo II inadecuadamente controladaEUCTR2009-018172-33-ESSANOFI AVENTIS GROUPE870
未知
不适用
A 4-MONTH, OPEN-LABEL, MULTICENTER STUDY TO EXPLORE THE SAFETY AND TOLERABILITY OF FINGOLIMOD 0.5 MG IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS.PER-002-12OVARTIS BIOSCIENSES PERU S.A.,27